In a span of a month, Exact Sciences has earned backing from organizations such as the Mayo Clinic and Group Health Cooperative for its Cologuard, and now Meriter-UnityPoint Health this week can be added to a growing list, Exact Sciences announced.

“Meriter’s adoption of Cologuard will help expand patient access to this clinically significant cancer screening technology,” Exact Sciences President, CEO and Chairman Kevin Conroy said in a statement. “We look forward to working with the healthcare providers at Meriter toward a future where colorectal cancer is identified earlier and survived more often.”

Cologuard is the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer. It is available by prescription only.